AIM Immunotech Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: AIM Immunotech Inc.
Filing Date: May 20, 2026
Event: Entry into a Material Definitive Agreement for a registered direct offering and concurrent private placement of warrants.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Common Shares Issued | 7,519,351 |
| Offering Price per Share | $0.325 |
| Gross Proceeds (Registered Offering) | Approx. $2.4 million |
| Common Warrants Issued | 15,038,702 (2x share count) |
| Warrant Exercise Price | $0.325 |
| Warrant Expiration | 5 years from Stockholder Approval Date |
| Potential Additional Proceeds (Full Warrant Exercise) | Approx. $4.9 million |
| Placement Agent Fees | 8.0% cash fee + 0.75% management fee + 6.0% of shares in warrants |
| Anticipated Stockholders' Equity Post-Closing | At least $6.0 million |
Material Changes and Transaction Structure
- Capital Raise: The Company entered into a Securities Purchase Agreement to sell shares in a registered direct offering and warrants in a concurrent private placement.
- Warrant Terms: Common Warrants are exercisable only after stockholder approval. They may be exercised on a cashless basis if no effective registration statement is available for resale.
- Placement Agent: Ladenburg Thalmann & Co. Inc. was appointed as the placement agent. They received warrants to purchase 451,161 shares (6.0% of the offering) at an exercise price of $0.40625.
- Registration Obligations: The Company must file a Form S-1 for the resale of warrants by June 8, 2026, and use commercially reasonable efforts to make it effective within 60 to 90 days.
Outlook, Risks, and Management Commentary
- Closing Date: Expected on or about May 21, 2026, subject to customary conditions.
- Uncertainty of Warrant Exercise: Management explicitly states it cannot predict when or if the Common Warrants will be exercised for cash.
- Liquidity Impact: The transaction is intended to bolster liquidity, with the Company anticipating at least $6.0 million in stockholders' equity upon closing.
- Regulatory Risk: The ability to exercise warrants for cash depends on the effectiveness of a future registration statement.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received after deducting offering expenses.
- Confirm the timeline for stockholder approval required to make the Common Warrants exercisable.
- Monitor the filing and effectiveness of the Form S-1 registration statement for warrant resale (deadline June 8, 2026).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Assess the dilution impact of the 15,038,702 warrants and 451,161 placement agent warrants on existing shareholders.